Neupogen (filgrastim) / Kyowa Kirin, Amgen - LARVOL DELTA

Interim analysis of efficacy and safety for ALLG MM25 (Viber-M): A phase I b/II study of venetoclax, iberdomide and dexamethasone for patients in first or second relapse of multiple myeloma with t(11; 14) (ASH 2025) - "Given the high attrition rates in patient numbers at each relapse,prioritising effective treatments early in the disease course is vital.In the era of lenalidomide (Len)-based induction and maintenance, there is need for a Len-free regimenat relapse. Iberdomide (Iber) is a potent oral cereblon E3 ligase modulator (CELMoD)...G3/4 TEAEs were reported in 11 patients (55%), with neutropenia being the most common(45%); 12 patients (60%) required filgrastim support...As of data cutoff, 44 of 50 patients have been enrolled. The planned interim analysis was conducted forthe first 20 patients (median age 65 years; range 41-83) following completion of three treatment cycles.Of these, 12 (60%) underwent planned dose escalation over three cycles, and 8 (40%) over two cycles. Themajority (75%) had one prior LOT."

Clinical • Febrile Neutropenia • Hematological Malignancies • Infectious Disease • Lymphoma • Multiple Myeloma • Neutropenia • Targeted Protein Degradation • Thrombocytopenia • CRBN

RARE PRESENTATIONS OF DUODENAL METASTASES ARISING FROM PENILE AND HEAD-AND-NECK SQUAMOUS CELL CARCINOMAS (WRMC 2026) - "Within a year, he had right inguinal lymph node (ILN) recurrence followed by lymphadenectomy (LND) + adjuvant Pembrolizumab (PB)...He began TPF therapy (5-fluorouracil, carboplatin, cisplatin), complicated by anemia and neutropenia from the DM, requiring transfusions, cefepime, and filgrastim...Patients might present with nonspecific symptoms such as nausea, vomiting, abdominal pain and weight loss and clinicians should be wary of such symptoms. We hope this series sheds light on maintaining a broad differential diagnosis, including malignancies in atypical situations and tailoring individual care towards patients."

Gastrointestinal Disorder • Head and Neck Cancer • Lung Cancer • Neutropenia • Oncology • Palliative care • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Patients with Multiple Sclerosis Above age 60 Have Neurological Responses to Autologous Hematopoietic Stem Cell Transplants Similar To Younger Individuals: A Single-Center Experience (ACTRIMS Forum 2026) - "Background & Objectives: To evaluate the neurological response of MS patients treated with TCHa using the “Mexican method” (2), focusing on changes in the Expanded Disability Status Scale (EDSS) (3) and stratifying the results by age. This prospective study included 1,438 MS patients treated with the “Mexican method” (high-dose cyclophosphamide, rituximab, dexamethasone, filgrastim, and MESNA) (2). The overall PR rate in people with MS who received aHCT using the "Mexican method" was 75.1%, similar in patients older than and younger than 60 years (4,5). The rate of early procedural complications was slightly higher in patients older than 60 years. Therefore, being older than 60 years should not be considered a reason to deny aHCT to patients with MS."

Clinical • Bone Marrow Transplantation • CNS Disorders • Multiple Sclerosis • Transplantation

The Number of CD34⁺ Cells Employed in Autologous Hematopoietic Stem Cell Transplantation for Persons With Multiple Sclerosis Is Not Related to the Neurological Outcome of the Procedure (ACTRIMS Forum 2026) - "Mobilization used cyclophosphamide (50 mg/kg) and filgrastim (10 µg/kg/day); products were infused fresh without cryopreservation. Conditioning followed the “Mexican Method” (high-dose cyclophosphamide + rituximab)... Thus, aHSCT induces neurological benefit in MS independent of CD34⁺ dose, supporting the efficacy of the outpatient “Mexican Method”."

Bone Marrow Transplantation • CNS Disorders • Multiple Sclerosis • Transplantation • CD34

PALETTE: Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial (clinicaltrials.gov) - P2 | N=2000 | Not yet recruiting | Sponsor: Assistance Publique - Hôpitaux de Paris | Phase classification: P3 ➔ P2 | Trial completion date: Apr 2032 ➔ May 2031 | Trial primary completion date: May 2029 ➔ Jun 2028

Pan tumor • Phase classification • Trial completion date • Trial primary completion date • Infectious Disease • Septic Shock

CD45RA-depleted CD19-CAR T Cell Consolidation After TCR??+ T Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma (clinicaltrials.gov) - P1 | N=60 | Not yet recruiting | Sponsor: St. Jude Children's Research Hospital | Initiation date: Dec 2025 ➔ May 2026

Trial initiation date • Hematological Malignancies • Lymphoma • Oncology • Pediatrics • Transplantation

ENGRAFTMENT SYNDROME IN AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION: INCIDENCE, ASSOCIATED FACTORS AND CLINICAL IMPACT (EBMT 2026) - "Additional data included CRP and procalcitonin at fever, time to neutrophil recovery, use or withdrawal of filgrastim, steroid treatment, length of stay, ICU admission and day +100 mortality... In our single-centre ASCT cohort (2023–2025), engraftment syndrome defined by the Maiolino criteria was a frequent complication associated with increased inflammatory response and longer hospitalisation, without a clear impact on early mortality. Amyloidosis appeared to be associated with a particularly high risk of ES."

Clinical • Amyloidosis • B Cell Non-Hodgkin Lymphoma • CNS Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma • Solid Tumor • T Cell Non-Hodgkin Lymphoma • Transplantation • CRP

Phase II study of TAS-OX (TAS-102 and oxaliplatin) plus bevacizumab for late-line colorectal cancer. (ASCO-GI 2023) - P2 | " Eligibility included measurable CRC previously treated with all approved drugs per TAS package insert (irinotecan, oxaliplatin, 5FU, anti-VEGF, anti-EGF) as appropriate, PS = 0-1, labs within usual range, neuropathy < grade 2, ability to take oral meds, appropriate contraception...For the first 40 pts, 385 cycles were given (mean = 7 cycles, median 8) with 18 pts (45%) requiring dose reductions (1 dose reduction = 9 pts, 2 = 6, 3 = 3), and 9 receiving (peg)/filgrastim... In patients with late-line CRC and candidates for TAS (trifluridine/tipiracil), treatment with TAS plus OX is both well tolerated and active. RR is higher than single agent and 78% (95% CI, 60-91%) of patients had stable disease or response, with 60% receiving 8 or more cycles. Randomized trials comparing to single agent TAS are warranted in this setting."

P2 data • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN HODGKIN LYMPHOMA: A 16-YEAR SINGLE-CENTER EXPERIENCE FROM EHU 1ST NOVEMBER OF ORAN, ALGERIA (EBMT 2026) - "ASCT was administered as first-line consolidation therapy in 53 patients with advanced-stage disease (stage III–IV) and in 102 patients with relapsed or refractory R/R HL.CD34⁺ hematopoietic stem cells were mobilized using granulocyte colony-stimulating factor (G-CSF) alone (filgrastim or lenograstim) at a dose of 15 µg/kg/day for 5 days, or in combination with plerixafor in cases of mobilization failure...The EAM regimen included a total dose of etoposide 800 mg/m², cytarabine 8 g/m², and melphalan 140 mg/m²... ASCT is a safe and effective treatment for patients with Hodgkin lymphoma. Using predominantly fresh grafts, the procedure showed low treatment-related mortality, rapid hematologic recovery, high remission rates, and durable long-term outcomes."

Clinical • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Transplantation • CD34

Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia (clinicaltrials.gov) - P2 | N=30 | Recruiting | Sponsor: University of Washington | Not yet recruiting ➔ Recruiting

Enrollment open • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Oncology • T Acute Lymphoblastic Leukemia

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia (clinicaltrials.gov) - P1 | N=47 | Not yet recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jan 2026 ➔ Jan 2027 | Initiation date: Oct 2025 ➔ Apr 2026 | Trial primary completion date: Jan 2026 ➔ Jan 2027

Trial completion date • Trial initiation date • Trial primary completion date • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Oncology • Transplantation • CD4

TRANSIENT ACUTE MYOCARDIAL INJURY DURING G-CSF MOBILIZATION IN HEALTHY PERIPHERAL STEM CELL DONORS: A CASE SERIES (EBMT 2026) - " We retrospectively collected data of 3 healthy donors (2 related and 1 unrelated) who developed acute myocardial injury during PBSC mobilization with biosimilar filgrastim (10 μg/kg/day for 5 consecutive days), observed at our Department between January 2024 and December 2025...In the 21-year-old female donor TTE showed preserved biventricular function and mild pericardial effusion that was treated with a short ibuprofen therapy... This is among the first reports of transient myocardial injury in healthy PBSC donors after receiving G‑CSF, suggesting a possible association. Cardiovascular adverse events should be considered in the differential diagnosis of donors reporting chest pain during HSCs mobilization, leading to prompt cardiological evaluation. Careful clinical monitoring and multidisciplinary management are crucial."

Clinical • Cardiovascular • Hypertension • Inflammation • Musculoskeletal Diseases • Musculoskeletal Pain • Myocardial Infarction • Obesity • Vasculitis

FIRST REPORT OF SUCCESSFUL, LIFESAVING AND TIMELY GRAFT RESCUE USING AN OFF-THE-SHELF CRYOPRESERVED, CADAVERIC MARROW IN TRANSPLANT FOLLOWING UNAVAILABILITY OF A LIVING MATCHED UNRELATED DONOR (EBMT 2026) - P | " A 34-year-old male with AML in first complete remission (CR1) began myeloablative fludarabine/busulfan conditioning in preparation for a 10/10 HLA-matched unrelated donor peripheral blood stem cell transplant. On Day -3 of conditioning, the donor experienced a severe allergic reaction to filgrastim, rendering the donor ineligible...GVHD prophylaxis consisted of tacrolimus, mycophenolate mofetil, and post-transplant cyclophosphamide... Timely access to an off-the-shelf marrow product prevented catastrophic graft failure or debilitating opportunistic infections. Day 0 was delayed by only 48 hours and the product was identified within 24 hours of request. A clinical trial using cryopreserved, off-the-shelf marrow grafts as primary graft option is underway (NCT #05589896)."

Acute Myelogenous Leukemia • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Transplantation • CD33 • CD34

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma (clinicaltrials.gov) - P2 | N=34 | Completed | Sponsor: National Cancer Institute (NCI) | Active, not recruiting ➔ Completed

Monotherapy • Trial completion • Alveolar Soft Tissue Sarcoma • Oncology • Sarcoma • Solid Tumor

NUMBER OF CD34 CELLS EMPLOYED IN AUTOLOGOUS HEMATOPOIETIC STEM-CELL TRANSPLANTATION FOR PERSONS WITH MULTIPLE SCLEROSIS IS NOT RELATED TO THE NEUROLOGICAL OUTCOME OF THE PROCEDURE (EBMT 2026) - "Mobilization used cyclophosphamide (50 mg/kg) and filgrastim (10 µg/kg/day); products were infused fresh without cryopreservation. Conditioning followed the "Mexican Method" (high-dose cyclophosphamide + rituximab)... Thus, aHSCT induces neurological benefit in MS independent of CD34⁺ dose, supporting the efficacy of the outpatient "Mexican Method"."

Bone Marrow Transplantation • CNS Disorders • Multiple Sclerosis • Transplantation • CD34

AML16: A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - P2 | N=206 | Active, not recruiting | Sponsor: St. Jude Children's Research Hospital | Trial primary completion date: Jun 2025 ➔ Sep 2025

Trial primary completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology

EVALUATION OF RELATED HEMATOPOIETIC STEM CELL DONORS IN THE CONTEXT OF FACT-JACIE STANDARDS IMPLEMENTATION (EBMT 2026) - "Among apheresis donors (median age 38.5 years; range 3–70; 100 females), 22 required more than one apheresis (10.7%), 30 (14.6%) required catheter placement, and 18 (8.8%) received plerixafor in addition to filgrastim. Stem cell donation, whether from peripheral blood or bone marrow, is a safe procedure in the context of implementing FACT-JACIE quality standards. The most frequent positive tests in our setting are syphilis and Chagas disease, which did not contraindicate donations. Conversely, detection of SCD was a rare event in our series and among patients with normal hemoglobin levels."

Bone Marrow Transplantation • Breast Cancer • CNS Disorders • Genetic Disorders • Hepatitis B • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Movement Disorders • Musculoskeletal Pain • Pulmonary Embolism • Sickle Cell Disease • Solid Tumor

INCIDENCE AND RISK FACTORS FOR POOR GRAFT FUNCTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IN A MULTICENTER COHORT (EBMT 2026) - "GVHD prophylaxis consisted of PTCy plus mycophenolate mofetil and a calcineurin inhibitor, using peripheral blood or bone marrow as the graft source...Management included thrombopoietin receptor agonists (TPO-Ras) (n=21), TPO-Ras plus filgrastim and erythropoietin (n=7), filgrastim alone (n=13), or transfusional support; seven patients required second-line therapy (CD34⁺ boost n=3, change of TPO-Ras n=3, second transplant n=1)...Letermovir prophylaxis was used in 56/427 seropositive receptors... In this multicenter cohort of allo-HSCT recipients receiving PTCy-based GVHD prophylaxis, the incidence of PGF was not higher than that reported in non-PTCy platforms. Bone marrow graft source, CMV reactivation within 6 months, and donor-specific anti-HLA antibodies were the main independent risk factors for PGF. These findings support optimization of graft quality and intensified CMV monitoring and prophylaxis strategies in patients receiving PTCy."

Clinical • Post-transplantation • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Lymphoma • Transplantation

Beyond Neutropenic Fever: Severe Multiorgan Immune-Related Toxicity Induced by Pembrolizumab. (PubMed, Cureus) - "We report the case of a 49-year-old woman with early-stage triple-negative breast cancer undergoing neoadjuvant chemotherapy with carboplatin, paclitaxel, and pembrolizumab, who presented to the emergency department with abdominal pain, diarrhea, nausea, and vomiting...Treatment with methylprednisolone 500 mg/day for three days, followed by tapering, filgrastim, and levothyroxine adjustment, led to rapid clinical and laboratory improvement. Pembrolizumab was permanently discontinued. This case highlights the importance of early recognition and aggressive management of potentially fatal immune-related toxicities associated with ICIs."

Journal • Acute Kidney Injury • Breast Cancer • Cardiovascular • Endocrine Disorders • Febrile Neutropenia • Gastroenterology • Gastrointestinal Disorder • Heart Failure • Hematological Disorders • Immunology • Nephrology • Oncology • Pain • Renal Disease • Solid Tumor • Triple Negative Breast Cancer

Canadian Cancer Trials Group (CCTG) LY.17: A Randomized Phase II Study Evaluating Novel Salvage Therapy Pre-Autologous Stem Cell Transplant (ASCT) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR-DLBCL) - Outcome of Rituximab-Dose-Intensive Cyclophosphamide, Etoposide, Cisplatin (R-DICEP) Versus R-GDP (ASH 2022) - "Introduction: The CCTG LY.12 trial established rituximab combined with gemcitabine, dexamethasone and cisplatin (R-GDP) as a standard salvage chemotherapy option prior to ASCT for patients (pts) with relapsed/refractory (RR) DLBCL (Crump JCO 2014)...This report involves the component of the trial that randomly allocated pts to either 1 cycle of inpatient R-DICEP (Rituximab 375mg/m2 IV or 1400mg sc days 1 and 5 plus dose-intensive Cyclophosphamide 5.25g/m2, Etoposide 1050mg/m2, Cisplatin 105mg/m2 divided over days 2-4, with daily filgrastim starting day 15 until apheresis of blood stem cells approximately between days 20-22) or to 3 cycles of outpatient R-GDP... Although the 17% improvement in ORR for R-DICEP vs R-GDP in the second interim analysis exceeded the pre-specified 10% threshold required proceed to full accrual of 64 pts in the R-DICEP arm, we decided to stop accrual to the R-DICEP arm of the LY.17 trial due to slow accrual, higher AE rates, and greater..."

Clinical • P2 data • Atrial Fibrillation • Bone Marrow Transplantation • Cardiovascular • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Infectious Disease • Inflammation • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pneumonia • Transplantation

PATIENTS WITH MULTIPLE SCLEROSIS ABOVE AGE 60 HAVE NEUROLOGICAL RESPONSES TO AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTS SIMILAR TO YOUNGER INDIVIDUALS: A SINGLE-CENTER EXPERIENCE (EBMT 2026) - "This protocol combines high-dose cyclophosphamide (200 mg/kg), rituximab 1 000 mg, filgrastim, and MESNA. Employing the "Mexican Method," PRR after aHSCT was 75.3%, with no significant difference between age groups. Although older patients had slightly more early complications, overall outcomes were similar, suggesting that age > 60 should not preclude aHSCT in MS."

Clinical • Bone Marrow Transplantation • CNS Disorders • Immunology • Inflammation • Multiple Sclerosis • Transplantation

Preemptive Tocilizumab with Bispecific Antibodies in Relapsed-Refractory Multiple Myeloma: A Case Series (TCT-ASTCT-CIBMTR 2026) - "Teclistamab (Tec), Talquetamab (Tal), and Elranatamab (Elra) are bispecific antibodies (BsAbs) approved for relapsed-refractory Multiple Myeloma (RRMM) which target CD3 on T- cells and either BCMA or GPRC5D, depending on the BsAb...The only incident of CRS occurred with a single patient who developed grade 1 CRS on C1D3 which resolved after one dose dexamethasone 10 mg...Supportive care was given during treatment including filgrastim to maintain absolute neutrophil 1.00 K/mcl, epoetin alfa to maintain hemoglobin above 10g/dl, and romiplostim to maintain platelets above 50 K/mcl...3. Evaluate the potential role and clinical impact of preemptive tocilizumab administration in reducing the incidence and severity of CRS without compromising therapeutic response in patients receiving bispecific antibodies."

Clinical • Hematological Malignancies • Infectious Disease • Multiple Myeloma • IL6

Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure (clinicaltrials.gov) - P1/2 | N=8 | Recruiting | Sponsor: Paul Szabolcs | Trial completion date: Dec 2026 ➔ Dec 2028 | Trial primary completion date: Dec 2025 ➔ Dec 2027

Trial completion date • Trial primary completion date • Aplastic Anemia • Bone Marrow Transplantation • Chronic Obstructive Pulmonary Disease • Hematological Disorders • Idiopathic Pulmonary Fibrosis • Immunology • Neutropenia • Pulmonary Disease • Respiratory Diseases • Transplantation

HEMATOLOGIC SHIFTS DURING HPC(A) AND THEIR INFLUENCE ON COLLECTION EFFICIENCY AND CD34+ CELL YIELD (EBMT 2026) - "The majority of aphereses (n = 264, 91.3%) were performed after mobilization with either G-CSF alone (n = 136) or G-CSF plus plerixafor (n = 128) at standard doses. ΔPLT emerged as the only robust predictor across all models, showing a positive association with CE1 and CE2 and an inverse association with AY. The remaining Δ-variables offered no independent contribution once multicollinearity was accounted for. Intra-apheresis platelet dynamics may therefore serve as a practical biomarker of apheresis system performance."

CD34

Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease (clinicaltrials.gov) - P2 | N=10 | Completed | Sponsor: National Cancer Institute (NCI) | Active, not recruiting ➔ Completed

Trial completion • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology